Romidepsin is an FDA approved HDAC inhibitor which exhibited synergistic inhibitory effects with TKIs in the treatment of non-small cell lung cancer (NSCLC) in preclinical models [21–23] and in clinical trials [24]. Here, HDAC9 is linked to non-small cell lung carcinoma.